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ABSTRACT 
 
We present case series of adult community-acquired bacterial meningitis treated with 
hypothermia. The major criteria for therapeutic hypothermia (TH) was impaired carbon dioxide 
reactivity (CO2R) assessed by Transcranial Doppler (TCD). In patients without temporal acoustic 
window, minor criteria (optic nerve sheath diameter ≥ 6.0 mm plus GCS ≤ 8 ) were required. 
According to our, although limited experience, the use of mild hypothermia in selected patients with 
community-acquired bacterial meningitis accompanied with appropriate monitoring could be a 
promising treatment tool.   
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INTRODUCTION 
 
Despite recent advances in antibiotic therapy and critical care, bacterial meningitis continues 
to impose high rates of morbidity and mortality.
1-4
 Given that bacterial meningitis freqently has 
associated poor outcomes, new treatment strategies are needed. Of particular interest is therapeutic 
hypothermia (TH). It has well documented neuroprotective effects and may have a potential use in 
selected patients with meningitis.
5,6
 We present case series of adult community-acquired bacterial 
meningitis treated with hypothermia and describe in detail the methods and the rationale for its use. 
 
PATIENTS AND METHODS 
 
In the period between February 2009 and May 2010, ten patients suffering from severe 
community-acquired bacterial meningitis were treated with hypothermia. All patients were 
mechanically ventilated. The following treatment protocol was applied in all patients: mild hypothermia 
(32-34
o 
C) accompanied with daily assessment of cerebrovascular carbon dioxide reactivity (CO2R) 
measured by Transcranial Doppler (TCD) and cerebral perfusion using the lactate-oxygen index (LOI) 
when available. The LOI was not measured in four patients because of difficult internal vein 
cannulation. Initial antimicrobial treatment consisted of ceftriaxone alone or in combination with 
ampicillin. Adjuvant steroid treatment was applied in seven patients.  
Despite therapeutic hypothermia, two patients died within 48 hours from admission because 
of refractory intracranial hypertension. Two patients with severe residual neurological deficits (GOS 2) 
died after discharge from ICU because of late-onset nosocomial sepsis more than a month upon 
admission. In the surviving six patients, the ICU stay ranged from 8 to 36 (mean 22) days.  
Of these survivors, two had severe and two had moderate residual neurological deficit, the 
most common being spastic hemiparesis and tetraparesis, respectively. One patient remained 
paraplegic with urinary incontinence due to severe pneumococcal myelitis. Two of the six survivors 
had a complete neurological recovery. The patients' demographic and clinical data are summarized in 
Tables 1-3. 
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The hospital Ethics Committee approved the treatment protocol and informed consent was 
obtained from the relatives of all patients. 
 
 
Transcranial Doppler ultrasound (TCD)  
TCD measurement of CO2 reactivity (CO2 R) was performed by using a Multidop 4 X (DWL, 
Sipplingen, Germany) with two 2-MHz pulsed wave probes 1.7 cm in diameter. The software used 
was TCD-8 for MDX (Version 8.0, Aaslid Rune).  
The left and right middle cerebral arteries (MCA) were insonated simultaneously through the 
temporal bone windows at a depth of 50-55 mm. The probes were secured to the head of the patient 
with a specially designed spectacle frame that permitted a constant angle of insonation. The mean 
blood flow velocities (MBFV) were continuously recorded during normal ventilation and during 
interventions (induced hypercapnia, norepinephrine infusion and hyperventilation). CO2 reactivity (CO2 
R) was assessed using the breath-holding method (disconnection from the ventilator for 30 seconds 
in a deep sedated and relaxed patient). The breath-holding index (BHI) was calculated by dividing the 
percentage of MBFV increase during breath holding by the time (in seconds) of apnea. The normal 
range of BHI is 1.03 – 1.65.
7
 
 
Optic nerve sheath diameter (ONSD) 
ONSD measurements were made using a B-scan ultrasound with a 10 MHz linear probe 
(Accuson CV70, Siemens Medical Solutions Inc., WA, USA) before and during the induced 
hypothermia. Optic nerve sheath diameter has been shown to be a very reliable measure of 
intracranial pressure (ICP). In adults ONSD greater than 5 mm correlated with a mean cerebrospinal 
fluid (CSF) pressure of 30 mmHg (elevated).
8,9 
 
Jugular bulb oximetry 
The jugular bulb catheter placement offers an opportunity for the measurement of SjO2 and 
calculation of lactate-oxygen index (LOI) using paired arterial and venous blood samples. The 
measurements were made daily during the period of hypothermia. Desaturation of jugular bulb 
venous blood (SjO2 < 55%) with increased cerebral lactate-oxygen index (LOI > 0.08) [derived from 
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arterio-jugular venous oxygen content difference (AjVDO2) and arterio-jugular venous lactate 
concentration difference (AVDL)] are reliable markers of cerebral hypoperfusion.
10,11
 Furthermore, 
increased SjO2 (>75%) and LOI with decreased AjVDO2 could be ominous signs of extreme 
intracranial hypertension and commonly represent a preterminal event.
10,11
  
Hypothermia 
We used an internal protocol designed to achieve mild hypothermia (rectal temperature of 32-
34
o
C ).  Hypothermia was induced by intravenous infusion of cold (+4
o
C - +8
o
C) isotonic saline (2000 
ml/1 h) and maintained with continuous veno-venous hemofiltration (CVVHF) by using a Prismaflex 
(Gambro Dasco S.p.A, Medolla, Italy) machine for 72 – 96 hours. The blood flow rate was set to 150 
ml/min, ultrafiltration rate (UFR) to zero ml/h and the replacement solution rate was set to 2000 ml/h. 
Enoxaparin was used for anticoagulation of the circuit. 
 
DISCUSSION 
 
While hypothermia has already been used for neuroprotection in a variety of neurological and 
non-neurological conditions, this method has been exceptionally applied to the treatment of central 
nervous system infections.
5,6,13-16
 Other adjunctive treatment options, such as the use of 
corticosteroids, despite their beneficial effects in majority of patients have not substantially changed 
disease outcomes among patients with most severe pneumococcal meningitis.
17
  
Common neurological sequelae in survivors of bacterial meningitis may result from neuronal 
damage, ischemic encephalopathy or ischemic stroke. In our opinion, current therapies do not 
adequately address the underlying pathophysiology leading to neurologic damage associated with 
bacterial meningitis. Current treatments are frequently aimed at reducing intracranial pressure and 
depend on cerebral vasoreactivity.
18,19
 In severe bacterial meningitis, however, cerebral blood flow 
(CBF) autoregulation is often damaged. Furthermore, cerebral metabolic oxygen demand (CMRO2) 
and CBF coupling is frequently disrupted and leads to multisegmental hypoperfusion or hyperemia.  
The use of mannitol in patients with impaired cerebral arterioles carbon dioxide reactivity (CO2R) 
carries the risk for paradoxical aggravation of brain edema because of possible mannitol leakage into 
the brain tissue . Therefore, the administration of mannitol should be discouraged in such patients. In 
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addition, the appropriate monitoring of cerebral perfusion pressure (CPP), intracranial pressure (ICP), 
cerebral oxygen demand, consumption and extraction in these patients is necessary.  
The effects of mild hypothermia may target the pathophysiological mechanisms that are in 
effect during bacterial meningitis because most of them are temperature dependent.
20,21
  
Hypothermia results in neuroprotection through a variety of mechanisms. Decreased body 
temperature causes reduced production of reactive oxygen and nitrogen species, inhibition of the 
neuroexcitatory cascade, a reduction in proinflammatory cytokine level, maintenance of blood-brain 
barrier integrity, decreased intracranial pressure, and finally decreased neuronal apoptosis.
22-28
 
Additionally, adverse events are noted to be rare. When those events occur, they are typically minor.
5 
 According to our framework, the selection of patients for induced hypothermia is primarily 
based on cerebral arterioles CO2 reactivity. The criteria for therapeutic hypothermia are GCS ≤ 8 
accompanied with optic nerve sheath diameter (ONSD) > 6.0 mm if the temporal acoustic window is 
absent and cerebral vasoreactivity cannot be assessed.  
 Because of strong correlation of BHI with the severity (particularly with GCS score) and the 
outcome of the disease, we defined the BHI level of ≤ 0.86 as inclusion criteria for hypothermia. 
Chemoregulation in our patients was severely impaired or completely absent. 
 We believe that marked reduction of CO2 reactivity, measured by TCD, accompanied with 
increased ONSD and altered mental status (GCS ≤ 8 ) reliably select patients who are candidates for  
urgent hypothermia induction. In patients with preserved CO2 reactivity, the use of hypothermia 
probably would not yield additional benefit when compared to the standard treatment regimen. The 
mortality rate in patients with bacterial meningitis and preserved vasoreactivity treated with standard 
regimen regardless of disease severity was zero (0/14) compared with 25% (5/20) in patients with 
impaired vasoreactivity (unpublished data). 
In all patients with jugular bulb catheter the measurements showed cerebral perfusion 
impairment (increased LOI) (Table 3). Vasopressors were used to support cerebral perfusion pressure 
(CPP). Low doses of norepinephrine infusion in addition to hypothermia were sufficient to significantly 
improve the MBFV and LOI without significant systemic hypertension. A marked reduction in ONSD 
during hypothermia was also noted (Table 3).  
 With respect to disease severity, the outcome of our patients was generally 
satisfactory (Table 1). If the standard treatment regimen had been applied the disease would likely 
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have been fatal. At admission, one patient had TCD signs of cerebral circulatory arrest while the 
others were elderly and had severe global cerebral hypoperfusion. The mortality rate in such patients 
reaches 69%.
3
  
While lowering of body temperature may take several hours in pyretic patients, CVVHF allows 
the maintenance of a stable body temperature. Our patients had no significant variations in body 
temperature. In addition, the use of CVVHF allows gradual rewarming of the patient upon recovery.  
While there is evidence from animal studies that hypothermia may be beneficial in meningitis 
and while scarce clinical experience suggests a role for hypothermia, large scale randomized clinical 
trials are needed.
27,28
 Inclusion criteria in these trials should be based primarily on the cerebral 
vasoreactivity status and not on pure randomisation and clinical impression. The use of hypothermia 
during meningitis is complex, but it likely has a physiologic role in treating bacterial meningitis. It may 
assist with the reduction in cerebral metabolism, cerebral blood volume (CBV), lowering of the 
intracranial pressure and suppression of the inflammatory host response allowing maintainance of 
sufficient cerebral perfusion pressure. Adequate and complete treatment balancing antimicrobial 
treatment, deep sedation, and controlled cerebral perfusion pressure early in the course of disease is 
critical. The recovery of CO2 reactivity cannot be expected before the fourth day of treatment 
according to our experience. Therefore, we recommended the use of hypothermia (if indicated) as 
soon as possible and at least during the first three days after presentation.  
Despite numerous favorable effects of hypothermia, a more comprehensive approach should 
be employed. It may be taken into account as an adjunctive therapy that has a role alongside 
established treatments. According to our findings, hypothermia in carefully selected patients holds 
promise.  
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TABLES 
Table 1.  Demographic and clinical data of patients with community-acquired bacterial meningitis treated with hypothermia  - Part one 
 
 
 
Patient 
No. 
Age/sex Day of 
disease* 
Coexisting 
conditions 
Seizures Etiology APACHE II GCS 
at 
admission 
GCS 
at discharge 
from ICU 
GOS
1 
Karnofsky 
score (%)
2
 
           
1 82/F 1 Otitis Yes S. pneumoniae (PSSP
†
) 31 8 15 4 50 
2 63/M 3 Otitis No S. pneumoniae (PRSP
‡
) 22 4 15    3**
 
60 
3 47/F 2 Immunocompromised
*** 
No S. pneumoniae (PSSP) 23 6 15 5 90 
4 71/F 2 Rectal adenocarcinoma  No S. pneumoniae (PSSP) 32 7 14 4 50 
5 76/M 1 Otitis No S. pneumoniae (PSSP) 24 9 NA 2 NA 
6 78/F 2 Immunocompromised Yes S. pneumoniae (PSSP) 33 3 NA 2 NA 
7 61/F 1 Acute renal failure No E. coli 33 3 NA 1 NA 
8 68/F 2 Immunocompromised, 
Pneumonia 
No S. pneumoniae (PSSP) 34 3 NA 1 NA 
9 70/M 1 Immunocompromised No S. pneumoniae (PSSP) 26 8 15 5 90 
10 75/F 1 Immunocompromised No S. pneumoniae (PSSP) 33 4 14 3 40 
 
 
Legend: 
 
*   day of disease on which hypothermia was started 
**  paraplegia caused by severe myelitis 
***Immunocompromised - the use of immunosuppressive drugs or the presence of diabetes mellitus, chronic renal failure or alcoholism 
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Table 2.  Demographic and clinical data of patients with community-acquired bacterial meningitis treated with hypothermia  - Part two 
 
 
 
Patient 
No. 
CSF cell count
3 
(cells/ mm
3
) 
 
CSF- blood 
glucose 
ratio
4
 
CSF protein 
concentration 
(mg/L)
5
 
CSF lactate 
concentration 
(mmol/L)
6
 
BHIm
7 
Vasopressor 
support 
Adjuvant 
dexamethasone 
treatment 
Duration of 
hypothermia 
(hours) 
Meningitis 
-related 
complications 
Hypothermia/CVVHF 
-related 
complications
 
           
1 36 000 0,0 7 450 18,0 N/A Yes Yes 72 none none 
2 200 000 0,0 12 100 15,9 0,876 Yes Yes 72 severe myelitis none 
3 9 216 0,47 1 843 8,6 0,610 No No 72 none none 
4 2 560 0,0 9 447 20,4 0,644 No Yes 72 none none 
5 1 160 0,03 11 936 25,9 0,350 No Yes 72 refractory brain edema none 
6 1 633 0,03 1 790 25,4 0,090 Yes Yes 96 ischemic stroke none 
7 12 997 0,39 7 348 18,7 0,210 Yes Yes 48 refractory brain edema none 
8 19 200 0,02 7 273 - 0,342 Yes Yes 48 ventriculitis, refractory 
brain edema 
none 
9 4 437 0,23 8 533 19,3 0,495 No No 96 none moderate amylase increase 
10 4 266 0,0 6 031 12,4 0,0 Yes No 96 ischemic 
leukoencephalopathy 
none 
 
 
Legend: 
 
1
 Score on Glasgow Outcome Scale - at discharge from ICU  [1(death), 2(vegetative state), 3(severe disability), 4(moderate disability), 5(mild or no disability)] 
2
 Karnofsky performance score - at discharge from ICU 
3
 CSF white cell count (normal value: < 5 cells/mm
3
)  
4
 CSF-blood glucose ratio (normal value: > 0,4) 
5
 CSF protein concentration (normal range: 150-450 mg/L) 
6
 CSF lactate concentration (normal range: 1,58-2,03 mmol/L) 
7
 Mean breath-holding index - at admission to ICU 
 
† 
PSSP = penicillin-susceptible Streptococcus pneumoniae    
‡  
PRSP = penicillin-resistant Streptococcus pneumoniae 
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Table 3.   The brain edema and cerebral perfusion indicators before and during therapeutical hypothermia 
 
 
 
Patient 
No. 
Duration of hypothermia (hours) 
 0  24  48  72  
  BHIm
1 
ONSD-
Right 
2
 
ONSD-
Left 
LOI
3
  BHIm
 
ONSD- 
Right 
ONSD-
Left 
LOI  BHIm
 
ONSD- 
Right 
ONSD-
Left 
LOI  BHIm
 
ONSD- 
Right 
ONSD-
Left 
LOI  
1  - 6,6 6,8 0,153  - 3,7 4,9 0,034  - 3,5 5,0 0,009  - - - 0,01  
2   0,876 6,6 6,6 -  0,850 6,0 6,0 -  0,910 5,6 5,7 -  1,000 4,7 5,0 -  
3  0,610 7,4 6,8 0,060  0,584 6,3 5,9 0,029  0,385 5,9 5,9 0,018  0,875 4,8 5,0 0,019  
4  0,644 6,4 6,0 0,440  0,650 6,0 5,6 0,007  0,580 5,6 5,0 0,002  0,780 5,0 4,5 0,021  
5  0,350 6,6 6,5 -  0,420 6,3 6,1 -  0,382 5,5 5,6 -  0,413 - - - - 
6  0,090 7,1 7,4 -  0,00 6,3 7,4 -  0,272 7,1 6,9 -  - - - -  
7  0,210 6,2 6,8 -  0,838 5,7 5,8 -  0,230 5,8 6,0 -  - - - -  
8  0,342 6,4 6,0 0,114  0,410 6,2 5,9 0,080  0,450 6,3 5,9 0,090  - - - -  
9  0,495 7,6 7,4 0,036  0,060 6,8 6,4 0,060  0,380 5,9 5,5 0,033  0,550 - - 0,010  
10  0,0 6,1 6,0 0,074  0,0 5,8 5,5 0,078  0,744 5,6 5,3 0,060  0,710 - - 0,040  
 
 
 
Legend: 
 
1
 BHIm = mean breath holding index (normal range: 1,03 – 1,65) 
2
 ONSD = optic nerve sheath diameter (normal value < 5,0 mm) 
3
 LOI = lactate-oxygen index (normal value < 0,03) 
 
 
 
 
 
